GlassScriptPhysician profile
Glory Abuajah
NPI 1073021002
$607.65
in general payments reported to CMS, 2019-2025
14 companies · $49.52 in 2025
The $49.52 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.09 · 2022: $182 · 2024: $289 · 2025: $49.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $24.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.34 |
| Education | $24.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219.75 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $53.58 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $49.53 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $46.45 | 2021-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $43.59 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.49 | 2022 | |
| Amgen INC. | $26.03 | 2024 | Aranesp, Tavneos, Parsabiv |
| Horizon Therapeutics Plc | $25.44 | 2021 | |
| Akebia Therapeutics INC | $24.32 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.10 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.49 | 2022 | |
| Vifor Pharma, INC. | $17.51 | 2022 | |
| Glaxosmithkline, LLC. | $15.90 | 2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glory Abuajah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.